Business & Regulation

The FDA has accepted TraceLink's blockchain and digital recall projects into its DSCSA Pilot Program.

Our animation explores the unique challenges a "no-deal" Brexit poses for the drug development and advanced therapy sectors.

We sit down with Nigel Theobald, Chief Executive, N4 Pharma. He tells us the story of his career and offers some advice for budding entrepreneurs.

Scouting for new leadership, prices hikes and successful acquisitions. What’s new for pharma in business?

Orphan drugs for rare diseases represent a significant unmet medical need for pharma, but commercialication can be tricky...

Nominations are now open for The Medicine Maker 2020 Power List.

How will the industry shape up over the next five years?

High quality excipients make all the difference to the drug development process. And yet, for years, excipients were often overlooked by the industry.

John McCafferty, CEO of IONTAS, explains how his company’s work in mammalian cells could bring biopharmaceuticals to market faster.

What are the consequences of allowing patients to purchase cell and gene therapies directly from hospitals?